Staphylococcal persistence due to biofilm formation in synovial fluid containing prophylactic cefazolin

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 2122-2128

  Dastgheyb, Sana S ^a,c   Hammoud, Sommer ^b   Ketonis, Constantinos ^a,b   Liu, Andrew Yongkun ^a   Fitzgerald, Keith ^a   Parvizi, Javad ^b   Purtill, James ^b   Ciccotti, Michael ^b   Shapiro, Irving M ^a   Otto, Michael ^c   Hickok, Noreen J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b ROTHMAN INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOY; ANTIBIOTIC AGENT; CEFAZOLIN; CHROMIUM; COBALT; MOLYBDENUM; TITANIUM; WHEAT GERM AGGLUTININ; ANTIINFECTIVE AGENT; TITANIUM ALLOY (TIAL6V4);

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACTERIAL SURVIVAL; BACTERIUM ADHERENCE; BACTERIUM CONTAMINATION; BACTERIUM ISOLATE; BIOFILM; BONE PIN; COLONY FORMING UNIT; CONFOCAL LASER MICROSCOPY; HUMAN; NONHUMAN; ORTHOPEDIC IMPLANT; ORTHOPEDIC SURGERY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; SYNOVIAL FLUID; TOTAL KNEE REPLACEMENT; ANTIBIOTIC RESISTANCE; BONE NAIL; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIAL ADHESION; BIOFILMS; BONE NAILS; CEFAZOLIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; SYNOVIAL FLUID; TITANIUM;

EID: 84949115429     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04579-14     Document Type: Article

References (33)

1. Pulido L, Ghanem E, Joshi A, Purtill JJ, Parvizi J. 2008. Periprosthetic joint infection: The incidence, timing, and predisposing factors. Clin Orthop Relat Res 466:1710 -1715. http://dx.doi.org/10.1007/s11999-008-0209-4.
2. Kurtz SM, Lau E, Schmier J, Ong KL, Zhao K, Parvizi J. 2008. Infection burden for hip and knee arthroplasty in the United States. J Arthroplasty 23:984-991. http://dx.doi.org/10.1016/j.arth.2007.10.017.
3. Kurtz SM, Lau E, Watson H, Schmier JK, Parvizi J. 2012. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty 27:61-65 e61. http://dx.doi.org/10.1016/j.arth.2012.02.022.
4. Borens O, Corvec S, Trampuz A. 2012. Diagnosis of periprosthetic joint infections. Hip Int 22(Suppl 8):S9 -S14. http://dx.doi.org/10.5301/HIP.2012.9565.
5. World Health Organization. 2009. WHO guidelines for safe surgery 2009: safe surgery saves lives. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/publications/2009/9789241598552-eng.pdf.
6. Block JE, Stubbs HA. 2005. Reducing the risk of deep wound infection in primary joint arthroplasty with antibiotic bone cement. Orthopedics 28: 1334-1345. http://dx.doi.org/10.3928/0147-7447-20051101-13.
7. Darouiche RO. 2003. Antimicrobial approaches for preventing infections associated with surgical implants. Clin Infect Dis 36:1284-1289. http://dx.doi.org/10.1086/374842.
8. Schurman DJ, Hirshman HP, Kajiyama G, Moser K, Burton DS. 1978. Cefazolin concentrations in bone and synovial fluid. J Bone Joint Surg Am 60:359-362.
9. McAllister TA, Tait SC, Perman MG, Park AC. 1976. Clinical bacteriology of cephazolin. Scott Med J 20:220-227.
10. de Lalla F. 2001. Antibiotic prophylaxis in orthopedic prosthetic surgery. J Chemother 13(Suppl 2):48-53. http://dx.doi.org/10.1179/joc.2001.13.Supplement-2.48.
11. Somekh E, Golan T, Tanay A, Poch F, Dan M. 1999. Concentration and bactericidal activity of fusidic acid and cloxacillin in serum and synovial fluid. J Antimicrob Chemother 43:593-596. http://dx.doi.org/10.1093/jac/43.4.593.
12. Somekh E, Heifetz L, Dan M, Poch F, Hafeli H, Tanai A. 1996. Penetration and bactericidal activity of cefixime in synovial fluid. Antimicrob Agents Chemother 40:1198-1200.
13. Ritter MA, Barzilauskas CD, Faris PM, Keating EM. 1989. Vancomycin prophylaxis and elective total joint arthroplasty. Orthopedics 12:1333-1336.
14. Gruber BF, Miller BS, Onnen J, Welling R, Wojtys EM. 2008. Antibacterial properties of synovial fluid in the knee. J Knee Surg 21:180-185. http://dx.doi.org/10.1055/s-0030-1247816.
15. Inman RD, Chiu B. 1996. Comparative microbicidal activity of synovial fluid on arthritogenic organisms. Clin Exp Immunol 104:80-85. http://dx.doi.org/10.1046/j.1365-2249.1996.d01-650.x.
16. Pruzanski W, Leers WD, Wardlaw AC. 1974. Bacteriolytic and bactericidal activity of sera and synovial fluids in rheumatoid arthritis and in osteoarthritis. Arthritis Rheum 17:207-218. http://dx.doi.org/10.1002/art.1780170303.
17. Pirnazar P, Wolinsky L, Nachnani S, Haake S, Pilloni A, Bernard GW. 1999. Bacteriostatic effects of hyaluronic acid. J Periodontol 70:370-374. http://dx.doi.org/10.1902/jop.1999.70.4.370.
18. Dastgheyb S, Parvizi J, Shapiro IM, Hickok NJ, Otto M. Effect of biofilms on recalcitrance of staphylococcal joint infection to antibiotic treatment. J Infect Dis, in press.
19. Ackerman D, Lett P, Galat DD Jr, Parvizi J, Stuart MJ. 2008. Results of total hip and total knee arthroplasties in patients with synovial chondromatosis. J Arthroplasty 23:395-400. http://dx.doi.org/10.1016/j.arth.2007.06.014.
20. Jacovides CL, Kreft R, Adeli B, Hozack B, Ehrlich GD, Parvizi J. 2012. Successful identification of pathogens by polymerase chain reaction (PCR)-based electron spray ionization time-of-flight mass spectrometry (ESI-TOF-MS) in culture-negative periprosthetic joint infection. J Bone Joint Surg Am 94:2247-2254. http://dx.doi.org/10.2106/JBJS.L.00210.
21. Malone CL, Boles BR, Lauderdale KJ, Thoendel M, Kavanaugh JS, Horswill AR. 2009. Fluorescent reporters for Staphylococcus aureus. J Microbiol Methods 77:251-260. http://dx.doi.org/10.1016/j.mimet.2009.02.011.
22. Jefferson KK, Cerca N. 2006. Bacterial-bacterial cell interactions in biofilms: detection of polysaccharide intercellular adhesins by blotting and confocal microscopy. Methods Mol Biol 341:119-126. http://dx.doi.org/10.1385/1-59745-113-4:119.
23. Dhawan VK, Maier MK, Nayyar M, Chuah SK, Thadepalli H. 1984. In vitro activity of cefmenoxime, cefotaxime, latamoxef, cefazolin, nafcillin and vancomycin against 53 endocarditis and bacteremic strains of Staphylococcus aureus. Chemotherapy 30:328-330. http://dx.doi.org/10.1159/000238288.
24. Antoci V Jr, King SB, Jose B, Parvizi J, Zeiger AR, Wickstrom E, Freeman TA, Composto RJ, Ducheyne P, Shapiro IM, Hickok NJ, Adams CS. 2007. Vancomycin covalently bonded to titanium alloy prevents bacterial colonization. J Orthop Res 25:858-866. http://dx.doi.org/10.1002/jor.20348.
25. Costerton JW. 2005. Biofilm theory can guide the treatment of devicerelated orthopaedic infections. Clin Orthop Relat Res 437:7-11. http://dx.doi.org/10.1097/00003086-200508000-00003.
26. Li D, Gromov K, Soballe K, Puzas JE, O'Keefe RJ, Awad H, Drissi H, Schwarz EM. 2008. Quantitative mouse model of implant-associated osteomyelitis and the kinetics of microbial growth, osteolysis, and hu-moral immunity. J Orthop Res 26:96 -105. http://dx.doi.org/10.1002/jor.20452.
27. Mini E, Grassi F, Cherubino P, Nobili S, Periti P. 2001. Preliminary results of a survey of the use of antimicrobial agents as prophylaxis in orthopedic surgery. J Chemotherapy 13(Suppl 2):73-79. http://dx.doi.org/10.1179/joc.2001.13.Supplement-2.73.
28. Norden CW. 1991. Antibiotic prophylaxis in orthopedic surgery. Rev Infect Dis 13(Suppl 10):S842-S846. http://dx.doi.org/10.1093/clinids/13.Supplement-10.S842.
29. Yamada K, Matsumoto K, Tokimura F, Okazaki H, Tanaka S. 2011. Are bone and serum cefazolin concentrations adequate for antimicrobial prophylaxis? Clin Orthop Relat Res 469:3486-3494. http://dx.doi.org/10.1007/s11999-011-2111-8.
30. Jebens EH, Monk-Jones ME. 1959. On the viscosity and pH of synovial fluid and the pH of blood. J Bone Joint Surg Br 41-B:388-400.
31. Berry CW, Moore TJ, Safar JA, Henry CA, Wagner MJ. 1992. Antibacterial activity of dental implant metals. Implant Dent 1:59-65. http://dx.doi.org/10.1097/00008505-199200110-00006.
32. Gómez-Barrena E, Esteban J, Medel F, Molina-Manso D, Ortiz-Perez A, Cordero-Ampuero J, Puertolas JA. 2012. Bacterial adherence to separated modular components in joint prosthesis: A clinical study. J Orthop Res 30:1634-1639. http://dx.doi.org/10.1002/jor.22114.
33. American Academy of Orthopaedic Surgeons. 2004. Recommendations for the use of intravenous antibiotic prophylaxis in primary total joint arthroplasty. AAOS information statement, information statement 1027. American Academy of Orthopaedic Surgeons, Rosemont, IL.